GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » EBIT per Share

Statera BioPharma (STU:7CB) EBIT per Share : €-0.45 (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma EBIT per Share?

Statera BioPharma's EBIT per Share for the three months ended in Sep. 2022 was €-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 was €-0.45.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Statera BioPharma's EBIT per Share or its related term are showing as below:

STU:7CB's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Statera BioPharma's EBIT for the three months ended in Sep. 2022 was €-1.56 Mil.


Statera BioPharma EBIT per Share Historical Data

The historical data trend for Statera BioPharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma EBIT per Share Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
EBIT per Share
-0.10 -0.35 -0.74

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.30 -0.20 -0.16 -0.05 -0.03

Statera BioPharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Statera BioPharma's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

EBIT per Share(A: Dec. 2021 )
=EBIT/Shares Outstanding (Diluted Average)
=-25.946/35.110
=-0.74

Statera BioPharma's EBIT per Share for the quarter that ended in Sep. 2022 is calculated as

EBIT per Share(Q: Sep. 2022 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.561/50.234
=-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Statera BioPharma  (STU:7CB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Statera BioPharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (STU:7CB) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines